Latest Headlines

Latest Headlines

Personalized brain cancer vaccine improves survival

Phase II data for Agenus' HSPPC-96 vaccine (also known as vitespen) showed glioblasoma patients living longer, which could offer a glimmer of hope.

Is Agenus on GSK's shopping list?

It's been a busy week or two for GlaxoSmithKline ($GSK)--the company has extended its agreement with Agenus ($AGEN), submitted two vaccines for approval and created a joint venture.

Agenus inks Oncophage cancer vaccine deal with Russian company

Cancer vaccine developer Agenus has inked a licensing, development and manufacturing technology transfer agreement with Russian drug company NewVac. Under the deal, NewVac gets to manufacture, market...

Agenus encouraged by early HerpV results

Lexington, MA-based Agenus reported promising Phase I results of its recombinant therapeutic vaccine HerpV for the treatment of genital herpes in a study published in the journal Vaccine. The

Cancer immunotherapies in vogue as specialists seek a "cure"

Now that Provenge and Yervoy have been approved, specialists are keying in on a new generation of immunotherapies that promise to change the standard of care for cancer. As Stephen Hodi, director of